The California Biotech Law Blog

"IP technology counseling and negotiation."

Author: The Prinz Law Office is a San Francisco Bay area law firm that focuses its intellectual property counseling practice on clients in the high technology, life science, and e-commerce industries.

Blawg Related Categories: Intellectual Property Law • Internet Law • Science & Technology Law • States • California • Legal Information

Recent Posts from The California Biotech Law Blog

Genetic Engineering & Biotechology News Interviews Kristie Prinz
Following up on our recent coverage of the patent reform debate, Genetic Engineering & Biotechnology News recently interviewed me for their article Patent Reform Battle Pits Biotech against High-Tech. The interview addressed the competing perspectives of…
Patent Reform Debate Revived in Congress
Here we go again. . . .Patent reform is back on the table: two bills have been introduced and are again being debated in Congress. The first of the two bills, the Leahy-Hatch bill, S.…
Federal Circuit Rules on Case Involving New USPTO Patent Rules
The Federal Circuit issued a long-awaited decision late last week in the case of Tafas v. Doll. At issue in this case was whether or not the USPTO had the authority to adopt a set…
Biosimilars Legislation Introduced in House
Two biosimilars bills have just been introduced in the House, each of which would establish regulatory path for biosimilars to be approved. The first bill, HR 1427, the Promoting Innovation and Access to Life Saving…
Congress Reaches Compromise to Extend SBIR
The House and Senate have reached a compromise to extend SBIR through July 31, 2009, according to a report that broke late this evening by the SBIR Insider. The SBIR Insider reports that the House will originate…
Gilead Sciences to Buy CV Therapeutics for $1.4 Billion
Gilead Sciences has agreed to buy Palo Alto-based CV Therapeutics for $1.4 billion dollars. According to SF Gate, Gilead Sciences will pay $20 per share for CV Therapeutics, which reported $154.5 million in revenue in…
Genentech and Roche Agree on Acquisition Deal; Employees End Up as Big Winners
On Thursday, an agreement on the prospective deal we have been discussing for months finally was reached: Roche formally agreed to acquire Genentech for $95 per share at a total price of $46.8 billion. Who came out…
Roche Reported to Be Close to Deal in Genentech Acquisition
Roche is reportedly close to reaching a deal over the Genentech acquisition. The Wall Street Journal reported Monday night that the terms of the current deal under consideration would provide for a share price of…
SBIR/STTR Program Set to Expire Later This Month; Support for Reauthorization Waning
As we reported previously, he SBIR/STTR program is set to expire on March 20th of this month, unless Congress takes last minute emergency action to save it. Unfortunately, SBIR Insider author Rick Shindell reports that there…
Silicon Valley IP Licensing Law Blog
Silicon Valley IP Licensing Law Blog